ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2008) 16 P422

Macroprolactinaemia in men

Larisa K Dzeranova, Ekaterina N Giniyatullina, Ludmila Y Rozhinskaya, Nikolai P Goncharov & Anna D Dobracheva


National Research Centre for Endocrinology, Moscow, Russian Federation.


Background: It is known women suffer from macroprolactinaemia more frequently than men. Often men with unclear genesis of hyperprolactinaemia have normal or a little depressed Testosterone level. High macroprolactin level in blood serum can explain this type of hyperprolactinaemia.

Materials and methods: Sixty-four men with hyperprolactinaemia (Prl >600 mU/l) were studied. Clinical, biochemical and MRI methods were used. Prl and Testosterone levels were determined by fluorescence method. MonPrl was determined by PEG-precipitation (Delfia; Finland). Macroprolactin level was calculated from Prl and monPrl data. After investigation of 35 healthy men with normoprolactinaemia reference value were estimated: 74–390 mU/l. A recovery of macroprolactin more than 60% was accepted as macroprolactinaemia.

Results: Macroprolactinaemia was founded in 11 (I group) of 64 cases (17.1%). True hyperprolactinaemia was founded in 53 (II group) of 64 cases. All patients of II group have been taken cabergoline (median of dose – 2.5 mg/week). Median of Prl level in I group was 2356 mU/l. Median of Testosterone level was 10.4 nmol/l. The microadenomas were revealed in 3 men, macroadenomas – in 6 patients. Clinical symptoms (libido impairment, reduced sexual potency) were founded in 9 men, they all had increased monPrl level (978 mU/l). That is why all of these patients have been taken cabergoline treatment (Median dose-1.25 mg/week). In 2 patients from I group monPrl level was normal and dynamic control carried out. After 6 months median of Prl level was 689 nU/l, testosterone level-14.1 nmol/l. There were no clinical symptoms in all 9 men. monPrl level was normal in all patients (median-265 mU/l). Positive dynamics of the tumors volume was noted in 5 patients with macroadenomas (from 2.5 to 1.9 cm3) and in 2 patients with microadenomas (from 0.9 to 0.5 cm3).

Conclusions: This investigation revealed that macroprolactinaemia is founded in 17.1% in men with tumorous and not tumorous hyperprolactinaemia. MonPrl level was higher than reference value in 9 of 11 patients with macroprolactinaemia and they were treated by cabergoline. But cabergoline dose in I group was greatly lower than in II group. Therefore efficiency estimation should be determined on monPrl level, not on Prl level.

Article tools

My recent searches

No recent searches.

My recently viewed abstracts